Praktyka Lekarska Ewa Krzyzagorska
- Address
- Ul. Murawa 37a, 61-655 Poznan, Poland
Cardiovascular Diseases
The team at Praktyka Lekarska Ewa Krzyzagorska is evaluating a novel therapy aimed at lowering heart‑related events in patients with atherosclerotic cardiovascular disease who also carry excess weight.
- Cardiovascular outcome study assessing morbidity and mortality benefits
- Use of a GLP‑1 receptor agonist as an adjunct to standard care
- Focus on dual primary endpoints of heart attacks and strokes
This research reflects the site’s commitment to improving heart health for individuals facing both vascular disease and obesity, with a single investigator leading the effort in Poznań, Poland.
Nutritional and Metabolic Diseases
At the same clinic, investigators are testing a once‑weekly injectable designed to promote significant weight reduction in adults with obesity and type 2 diabetes.
- Evaluation of body‑weight change over a 64‑week period
- Comparison of the new agent versus placebo for safety and efficacy
- Integration with existing diabetes management strategies
The study highlights the site’s focus on metabolic health, aiming to provide new tools for weight management and diabetes control in the European patient community.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Amgen Inc.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praktyka Lekarska Ewa Krzyzagorska
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Maridebart Cafraglutide | 1 | Unknown | 2025-10-10 | 2025-10-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.